EGFR and cancer: Structural determinations of the EGFR [38]–[41] and ABL cancer mutants [42], [43] have suggested that molecular mechanisms of kinase activation by cancer mutations and activity signatures of cancer drugs may be associated with the dynamics of functional transitions between inactive and active kinase forms.